Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations

References

• van der Zwan S, DeMatteo RP. Gastrointestinal stromal tumor: 5 years later. Cancer104, 1781–1788 (2005).
   PubMedGoogle Scholar
• Nilsson B, Bümming P, Meis-Kindblom JM et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era: a population-based study in western Sweden. Cancer103, 821–829 (2005).
   PubMed Web of Science ®Google Scholar
• Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J. Clin. Oncol.22, 3813–3825 (2004).
   PubMed Web of Science ®Google Scholar
• Blay JY, Bonvalot S, Casali P et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO. Ann. Oncol.16, 566–578 (2005).
   PubMed Web of Science ®Google Scholar
• Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol.19(Suppl. 2), ii35–ii38 (2008).
   PubMed Web of Science ®Google Scholar
• DeMatteo RP, Lewis JJ, Leung D et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann. Surg.231, 51–58 (2000).
   PubMed Web of Science ®Google Scholar
• Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science279, 5577–5580 (1998).
   Google Scholar
• Heinrich MC, Corless CL, Duensing A et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science299, 708–710 (2003).
   PubMed Web of Science ®Google Scholar
• Rubin BP, Singer S, Tsao C et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res.61, 8118–8121 (2001).
   PubMed Web of Science ®Google Scholar
• Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med.344, 1052–1056 (2001).
   PubMed Web of Science ®Google Scholar
• Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet364, 1127–1134 (2004).
   PubMed Web of Science ®Google Scholar
• Debiec-Rychter M, Sciot R, Le Cesne A et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur. J. Cancer42, 1093–1103 (2006).
   PubMed Web of Science ®Google Scholar
• DeMatteo RP, Maki RG, Singer S et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann. Surg.245, 347–352 (2007).
   PubMedGoogle Scholar
• DeMatteo RP, Owzar C, Maki R et al. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. J. Clin. Oncol.25(Suppl. 2) (2007) (Abstract 10079).
   PubMedGoogle Scholar
• Mendel DB, Laird AD, Xin X et al.In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res.9, 327–337 (2003).
   PubMed Web of Science ®Google Scholar
• Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer. Mol. Cancer Ther.2, 471–478 (2003).
   PubMed Web of Science ®Google Scholar
• O’Farrell AM, Abrams TJ, Yuen HA et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood101, 3597–3605 (2003).
   PubMed Web of Science ®Google Scholar
• Murray LJ, Abrams TJ, Long KR et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin. Exp. Metastasis20, 757–766 (2003).
   PubMed Web of Science ®Google Scholar
• Kim DW, Jo YS, Jung HS et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J. Clin. Endocrinol. Metab.91, 4070–4076 (2006).
   PubMed Web of Science ®Google Scholar
• Pfizer Inc. SUTENT, Summary of Product Characteristics. January 2008 (2008).
   Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet368, 1329–1338 (2006).
   PubMed Web of Science ®Google Scholar
• Demetri GD, Huang X, Garrett CR et al. Novel statistical analysis of long-term survival to account for crossover in a Phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure. Presented at: The 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 30 May–3 June 2008 (Abstract 10524).
   Google Scholar
• Reichardt P, Kang Y, Ruka W et al. Detailed analysis of survival and safety with sunitinib (SU) in a worldwide treatment-use trial of patients with advanced GIST. Presented at: The 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 30 May–3 June 2008 (Abstract 10548).
   Google Scholar
• ESMO Guidelines Working Group. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol.18, ii27–ii29 (2007).
   PubMedGoogle Scholar
• Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med.347, 472–480 (2002).
   PubMed Web of Science ®Google Scholar
• Rankin C, von Mehren M, Blanke CD et al. Dose effect of imatinib (IM) in patients (pts) with metastatic GIST – Phase III sarcoma group study S0033. J. Clin. Oncol.22(Suppl. 14S) (2004) (Abstract 9005).
   PubMedGoogle Scholar
• Eisenberg BL. Combining imatinib with surgery in gastrointestinal stromal tumors: rationale and ongoing trials. Clin. Colorectal. Cancer6(Suppl. 1), S24–S29 (2006>).
   PubMed Web of Science ®Google Scholar
• Shinomura Y, Kinoshita K, Tsutsui S, Hirota S. Pathophysiology, diagnosis, and treatment of gastrointestinal stromal tumors. J. Gastroenterol.40, 775–780 (2005).
   PubMedGoogle Scholar
• Corless CL. Assessing the prognosis of gastrointestinal stromal tumors: a growing role for molecular testing. Am. J. Clin. Pathol.122, 11–13 (2004).
   PubMedGoogle Scholar
• Blanke CD, Rankin C, Demetri GD et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J. Clin. Oncol.26, 626–632 (2008).
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Maki RG, Corless CL et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib malate in imatinib-resistant. J. Clin. Oncol.26, 5352–5359 (2008).
   PubMed Web of Science ®Google Scholar
• Maki RG, Fletcher JA, Heinrich MC et al. Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). J. Clin. Oncol.23(16S), 9011 (2005).
   Google Scholar
• George S, Blay JY, Casali PG et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur. J. Cancer (2009) (Epub ahead of print).
   Google Scholar
• Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist13(Suppl. 2), 4–7 (2008).
   PubMed Web of Science ®Google Scholar
• Choi H, Charnsangavej C, de Castro Faria S et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. Am. J. Roentgenol183, 1619–1628 (2004).
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Van Glabbeke M, Verweij J et al. Absence of progression as assessed by RECIST predicts survival in advanced gastrointestinal stromal tumors treated with imatinib mesylate: analysis of the INTERGROUP EORTC–ISG–AGITG Phase III trial. J. Clin. Oncol. (2009) (In press).
   Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl Cancer Inst.92, 205–216 (2000).
   PubMed Web of Science ®Google Scholar
• Antoch G, Kanja J, Bauer S et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J. Nucl. Med.45, 357–365 (2004).
   PubMed Web of Science ®Google Scholar
• Prior JO, Montemurro M, Orcurto MV et al. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J. Clin. Oncol.20(27), 439–445 (2009).
   Google Scholar
• Lassau N, Lamuraglia M, Chami L et al. Gastrointestinal stromal tumours treated with imatinib: monitoring response with contrast-enhanced sonography. Am. J. Roentgenol.187, 1267–1273 (2006).
   PubMed Web of Science ®Google Scholar
• Shankar S, van Sonnenberg E, Desai J et al. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology235, 892–898 (2005).
   PubMed Web of Science ®Google Scholar
• Bui BN, Duffaud F, Hermine O, Hermine O, Le Cesne A. Preliminary efficacy and safety results of masitinib administered, front line in patients with advanced GIST. J. Clin. Oncol.25(18S) (2007) (Abstract 10025).
   PubMedGoogle Scholar
• Wagner AJ, Morgan JA, Chugh R et al. Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: clinical results from Phase I trial. J. Clin. Oncol.26 (2008) (Abstract 10503).
   PubMedGoogle Scholar
• Blay JY, Casali PG, Reichardt P et al. A Phase I study of nilotinib alone and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST): study update. J. Clin. Oncol.26(15S), 566s (2008) (Abstract 10553).
   Google Scholar
• Reichardt P, Pink D, Lindner T et al. A Phase I/II trial of the oral PKC-inhibitor PKC412 (PKC) in combination with imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM. J. Clin. Oncol.23(Suppl.), 136S (2005) (Abstract 3016).
   Google Scholar
• Palassini E, Fumagalli E, Coco P et al. Combination of PKC412 and sirolimus in a metastatic patient with PDGFRA-D842V gastrointestinal stromal tumor (GIST). J. Clin. Oncol.26(Suppl.), 748S (2008) (Abstract 21515).
   Google Scholar
• Poveda A, Maurel J, Cubedo R et al. Phase I–II trial of imatinib (IM) and low-dose doxorubicin (DX) in patients (pts) with advanced gastrointestinal stromal tumors (GIST), refractory to high-dose IM: a GEIS study. J. Clin. Oncol.26 (2008) (Abstract 10520).
   Google Scholar
• Casali PG, Fumagalli E, Bello A, George S. Safety and tolerability of sunitinib (SU) initiated 24 h after the last dose of imatinib (IM) in advanced GIST. J. Clin. Oncol.26(15S) (2008) (Abstract 10557).
   Google Scholar
• Gleevec® (imatinib mesylate) tablets prescribing information. Novartis Pharmaceuticals Corporation (2009).
   Google Scholar